1. Seattle Genetics commits to ensuring that all Seagen studies are integrated with the procedural building blocks to increase potential for diversity within our site and patient populations.

2. Seattle Genetics will build upon current Seagen clinical trial patient diversity composition of 9% to achieve double digit growth in 2021.